Diffuse alveolar hemorrhage in children with trisomy 21

Area of Science:

• Pediatric Pulmonology
• Genetics
• Immunology

Background:

• Respiratory conditions are a leading cause of morbidity and mortality in children with Trisomy 21 (T21).
• Diffuse alveolar hemorrhage (DAH) is more frequent in T21 but understudied, lacking standardized diagnostic and management protocols.
• This study aimed to identify children with T21 and DAH to understand contributing factors and improve outcomes.

Observation:

• Five pediatric cases of histology-proven DAH in T21 patients over 10 years were identified and analyzed.
• Literature review revealed 19 additional DAH cases in T21, predominantly from outside the US, with common features like anemia, respiratory distress, autoantibodies, and recurrence.
• Hemoptysis was infrequent; idiopathic pulmonary hemosiderosis was a common diagnosis.

Findings:

• Key diagnostic clues for DAH in T21 include respiratory distress, hypoxia, anemia, recurrent pneumonia, and ground-glass opacities.
• Identified DAH contributors in T21: structural lung abnormalities, pulmonary arterial hypertension, infection/aspiration, and autoimmune disease/immune dysregulation.
• Four of the five studied patients showed positive response to immune-modulating therapies like IVIG, glucocorticoids, and rituximab.

Implications:

• Increased clinical suspicion for DAH is crucial in children with T21, even without hemoptysis.
• Understanding risk factors and diagnostic clues can lead to earlier identification and intervention.
• Favorable response to immunosuppressive therapies suggests a significant autoimmune component in DAH within the T21 population.